Cargando…

Gestational Age Variation in Human Placental Drug Transporters

Patient and providers’ fear of fetal exposure to medications may lead to discontinuation of treatment, disease relapse, and maternal morbidity. Placental drug transporters play a critical role in fetal exposure through active transport but the majority of data are limited to the 3rd trimester, when...

Descripción completa

Detalles Bibliográficos
Autores principales: Goetzl, Laura, Darbinian, Nune, Merabova, Nana, Devane, Lindsay C., Ramamoorthy, Sammanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019509/
https://www.ncbi.nlm.nih.gov/pubmed/35462922
http://dx.doi.org/10.3389/fphar.2022.837694
_version_ 1784689299615121408
author Goetzl, Laura
Darbinian, Nune
Merabova, Nana
Devane, Lindsay C.
Ramamoorthy, Sammanda
author_facet Goetzl, Laura
Darbinian, Nune
Merabova, Nana
Devane, Lindsay C.
Ramamoorthy, Sammanda
author_sort Goetzl, Laura
collection PubMed
description Patient and providers’ fear of fetal exposure to medications may lead to discontinuation of treatment, disease relapse, and maternal morbidity. Placental drug transporters play a critical role in fetal exposure through active transport but the majority of data are limited to the 3rd trimester, when the majority of organogenesis has already occurred. Our objective was to define gestational age (GA) dependent changes in protein activity, expression and modifications of five major placental drug transporters: SERT, P-gp, NET, BCRP and MRP3. Apical brush border membrane fractions were prepared from fresh 1st, 2nd and 3rd trimester human placentas collected following elective pregnancy termination or planned cesarean delivery. A structured maternal questionnaire was used to identify maternal drug use and exclude exposed subjects. Changes in placental transporter activity and expression relative to housekeeping proteins were quantified. There was evidence for strong developmental regulation of SERT, NET, P-gp, BCRP and MRP3. P-gp and BCRP decreased with gestation (r = −0.72, p < 0.001 and r = −0.77, p < 0.001, respectively). Total SERT increased with gestation but this increase was due to a decrease in SERT cleavage products across trimesters. Uncleaved SERT increased with GA (r = 0.89, p < 0.001) while cleaved SERT decreased with GA (r = −0.94, p < 0.001). Apical membrane NET overall did not appear to be developmentally regulated (r = −0.08, p = 0.53). Two forms of MRP3 were identified; the 50 kD form did not change across GA; the 160 kD form was steady in the 1st and 2nd trimester and increased in the 3rd trimester (r = 0.24, p = 0.02). The 50 kD form was expressed at higher levels. The observed patterns of SERT, NET P-gp, BCRP and MRP3 expression and activity may be associated with transporter activity or decreased placental permeability in the 1st trimester to transporter specific substrates including commonly used psychoactive medications such as anti-depressants, anti-psychotics, and amphetamines, while transport of nutrients and serotonin is important in the 1st trimester. Overall these observations are consistent with a strong protective effect during organogenesis. 3rd trimester estimates of fetal exposure obtained from cord blood likely significantly overestimate early fetal exposure to these medications at any fixed maternal dose.
format Online
Article
Text
id pubmed-9019509
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90195092022-04-21 Gestational Age Variation in Human Placental Drug Transporters Goetzl, Laura Darbinian, Nune Merabova, Nana Devane, Lindsay C. Ramamoorthy, Sammanda Front Pharmacol Pharmacology Patient and providers’ fear of fetal exposure to medications may lead to discontinuation of treatment, disease relapse, and maternal morbidity. Placental drug transporters play a critical role in fetal exposure through active transport but the majority of data are limited to the 3rd trimester, when the majority of organogenesis has already occurred. Our objective was to define gestational age (GA) dependent changes in protein activity, expression and modifications of five major placental drug transporters: SERT, P-gp, NET, BCRP and MRP3. Apical brush border membrane fractions were prepared from fresh 1st, 2nd and 3rd trimester human placentas collected following elective pregnancy termination or planned cesarean delivery. A structured maternal questionnaire was used to identify maternal drug use and exclude exposed subjects. Changes in placental transporter activity and expression relative to housekeeping proteins were quantified. There was evidence for strong developmental regulation of SERT, NET, P-gp, BCRP and MRP3. P-gp and BCRP decreased with gestation (r = −0.72, p < 0.001 and r = −0.77, p < 0.001, respectively). Total SERT increased with gestation but this increase was due to a decrease in SERT cleavage products across trimesters. Uncleaved SERT increased with GA (r = 0.89, p < 0.001) while cleaved SERT decreased with GA (r = −0.94, p < 0.001). Apical membrane NET overall did not appear to be developmentally regulated (r = −0.08, p = 0.53). Two forms of MRP3 were identified; the 50 kD form did not change across GA; the 160 kD form was steady in the 1st and 2nd trimester and increased in the 3rd trimester (r = 0.24, p = 0.02). The 50 kD form was expressed at higher levels. The observed patterns of SERT, NET P-gp, BCRP and MRP3 expression and activity may be associated with transporter activity or decreased placental permeability in the 1st trimester to transporter specific substrates including commonly used psychoactive medications such as anti-depressants, anti-psychotics, and amphetamines, while transport of nutrients and serotonin is important in the 1st trimester. Overall these observations are consistent with a strong protective effect during organogenesis. 3rd trimester estimates of fetal exposure obtained from cord blood likely significantly overestimate early fetal exposure to these medications at any fixed maternal dose. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019509/ /pubmed/35462922 http://dx.doi.org/10.3389/fphar.2022.837694 Text en Copyright © 2022 Goetzl, Darbinian, Merabova, Devane and Ramamoorthy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Goetzl, Laura
Darbinian, Nune
Merabova, Nana
Devane, Lindsay C.
Ramamoorthy, Sammanda
Gestational Age Variation in Human Placental Drug Transporters
title Gestational Age Variation in Human Placental Drug Transporters
title_full Gestational Age Variation in Human Placental Drug Transporters
title_fullStr Gestational Age Variation in Human Placental Drug Transporters
title_full_unstemmed Gestational Age Variation in Human Placental Drug Transporters
title_short Gestational Age Variation in Human Placental Drug Transporters
title_sort gestational age variation in human placental drug transporters
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019509/
https://www.ncbi.nlm.nih.gov/pubmed/35462922
http://dx.doi.org/10.3389/fphar.2022.837694
work_keys_str_mv AT goetzllaura gestationalagevariationinhumanplacentaldrugtransporters
AT darbiniannune gestationalagevariationinhumanplacentaldrugtransporters
AT merabovanana gestationalagevariationinhumanplacentaldrugtransporters
AT devanelindsayc gestationalagevariationinhumanplacentaldrugtransporters
AT ramamoorthysammanda gestationalagevariationinhumanplacentaldrugtransporters